A Phase 3 interventional study of Rocatinlimab and Placebo in Prurigo Nodularis, sponsored by Amgen. Terminated at 192 sites in 30 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Prurigo with a site in United States — 4 open to participants now, 8 under way, 4 of them phase 3. Prurigo · United States.
Among the 23 studies in Prurigo with a site in United States, this one is the 2nd largest by enrollment of the 21 interventional ones that give a count, is one of 7 that started in 2024, is one of 10 in phase 3, and was the 19th registered.
38 studies on the registry are indexed under Prurigo; 10 are open to participants now.
Browse Prurigo studies →4 of the 23 studies in Prurigo with a site in United States are open now. Recruiting first, the newest first:
Beijing InnoCare Pharma Tech Co., Ltd. · Sites in United States, China, France and 2 more countries
Ages 18–75
Galderma R&D · Sites in United States, Germany
Ages 18+
Sanofi · Sites in United States
Ages 6 mo–17 yrs
University of Maryland, Baltimore · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Prurigo studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 12 · Phase 4 1
First in 2008; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 469 is above the median of 135 across 31 interventional studies indexed under Prurigo.
Median enrollment 140 across the 21 interventional studies, 355 across the 2 observational. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 23 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 167 (68%) have results posted.
Amgen has 1 study filed under Prurigo — fewer than ten, so there is no comparison to draw.
3 of the studies in Prurigo with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06293053Phase 3SanofiA Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis | 2027-10-28 |
| NCT07236099Beijing InnoCare Pharma Tech Co., Ltd.Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis | 2027-03 |
| NCT06988618Galderma R&DReal-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Prurigo with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of the study will be to evaluate the efficacy of rocatinlimab compared with placebo at week 24 on the patient-reported outcome (PRO) measure of pruritus and overall clinical assessment score (US only).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive rocatinlimab dose 1 subcutaneously (SC) during Treatment Period A and B.
Drug: Rocatinlimab
Participants will receive rocatinlimab dose 2 SC during Treatment Period A and B.
Drug: Rocatinlimab
Participants will receive matching placebo SC during Treatment Period A and B.
Drug: Placebo
Participants will receive open-label rocatinlimab dose 1 SC during Treatment Period B.
Drug: Rocatinlimab
SC Injection
Also known as: AMG 451
SC Injection
Global: Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Itch Score at Week 24
Time frame: Up to 24 weeks
US Only: Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Itch Score and Prurigo Nodularis Stage Assessment at Week 24
Time frame: Up to 24 weeks
Global: Number of Participants Achieving Improvement in Prurigo Nodularis Stage Assessment Score at Week 24
Time frame: Week 24
Global: Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Itch Score and Prurigo Nodularis Stage Assessment at Week 24
Time frame: Baseline and Week 24
Global: Percentage Improvement from Baseline in Weekly Average of Daily Itch Score at Week 24
Time frame: Baseline and Week 24
Global: Number of Participants Achieving Reduction in Weekly Average Daily Prurigo Nodularis Skin Pain Assessment at Week 24 in Those with Baseline NRS Above Cutoff
Time frame: Baseline and Week 24
US Only: Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Itch Score at Week 24
Time frame: Baseline and Week 24
US Only: Number of Participants with Improvement in Prurigo Nodularis Stage Assessment at Week 24
Time frame: Week 24
US Only: Percent Improvement from Baseline in Weekly Average of Daily Itch Score at Week 24
Time frame: Week 24
US Only: Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Skin Pain Assessment at Week 24 in Participants With Baseline Score Greater Than or Equal to a Cutoff Score
Time frame: Week 24
Change from Baseline in Weekly Average of Daily Itch Score at Weeks 24, 36 and 52
Time frame: Baseline, Week 24, Week 36 and Week 52
Percent Improvement from Baseline in Weekly Average of Daily Itch Score at Week 36 and 52
Time frame: Baseline, Week 36 and Week 52
Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Itch Score at Weeks 16, 36 and 52
Time frame: Baseline, Week 16, Week 36 and Week 52
Number of Participants Achieving Weekly Average of Daily Itch Score Less than a Cutoff Score at Week 36 and 52
Time frame: Week 36 and Week 52
Change from Baseline in Prurigo Nodularis Stage Assessment Score at Week 24, 36, and 52
Time frame: Baseline, Week 24, Week 36 and Week 52
Number of Participants Achieving Improvement in Prurigo Nodularis Stage Assessment Score at Weeks 36 and 52
Time frame: Week 36 and Week 52
Number of Participants Achieving Improvement in Prurigo Nodularis Activity Assessment Score at Weeks 24, 36 and 52
Time frame: Week 24, Week 36 and Week 52
Change from Baseline in Quality of Life Assessment Score at Weeks 24, 36 and 52
Time frame: Baseline, Week 24, Week 36 and Week 52
Number of Participants Achieving Reduction from Baseline in Quality of Life Assessment Score at Weeks 24, 36 and 52 in Participants with Baseline Score Greater Than or Equal to a Cutoff Score
Time frame: Baseline, Week 24, Week 36 and Week 52
Change from Baseline in Weekly Average of Daily Skin Pain Assessment Score at Weeks 24, 36 and 52
Time frame: Baseline, Week 24, Week 36 and Week 52
Change from Baseline in Weekly Average of Daily Sleep Disturbance Assessment Score at Weeks 24, 36 and 52
Time frame: Baseline, Week 24, Week 36 and Week 52
Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Sleep Disturbance Assessment Score at Weeks 24, 36 and 52 in Participants with Baseline Weekly Average Score Greater Than or Equal to a Cutoff Score
Time frame: Baseline, Week 24, Week 36 and Week 52
Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Itch Score and Prurigo Nodularis Stage Assessment at Week 36 and 52
Time frame: Baseline, Week 36 and Week 52
Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Skin Pain Assessment Score at Week 36 and 52 in Participants With Baseline Score Greater Than or Equal to a Cutoff Score
Time frame: Baseline, Week 36 and Week 52
Showing the first 100 of 192 sites across 30 countries. Choose a country and city above to see the rest.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Jul 2024 to primary completion in Apr 2026, 20 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: KHK4083